NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Huh? New NWBO international patent application published April 2021. Looks to me like it could be studied against non-heterogenous diseases like Covid variants. Can’t find much more on it yet. Hyperactivated DC against an antigen. See abstract below.

Received at International Bureau: 23 October 2020 (23.10.2020)

Information valid as of: 19 March 2021 (19.03.2021)

Report generated on: 25 December 2021 (25.12.2021)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2021/071977 15 April 2021 (15.04.2021) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2020/054621 07 October 2020 (07.10.2020) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/912,005 (US) 07 October 2019 (07.10.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 39/00 (2006.01)

(71) Applicant(s):
NORTHWEST BIOTHERAPEUTICS, INC. [US/US]; 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)
BOSCH, Marnix, Leo [--/--]; Statenplein 6 2582EX 's Gravenhage (NL) (for all designated states)
POWERS, Linda, F. [--/--]; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)
BOYNTON, Alton, L. [US/US]; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)

(72) Inventor(s):
BOSCH, Marnix, Leo; Statenplein 6 2582EX 's Gravenhage (NL)
POWERS, Linda, F.; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US)
BOYNTON, Alton, L.; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US)

(74) Agent(s):
POOR, Brian, W.; Christensen O'Connor Johnson Kindness PLLC 1201 Third Avenue, Suite 3600 Seattle, WA 98101 (US)

(54) Title (EN): IN VITRO METHODS AND COMPOSITIONS FOR ENHANCING THE ACTIVATION OF DENDRITIC CELLS AND T CELLS, AND FOR INDUCING A TH-1 IMMUNE RESPONSE
(54) Title (FR): PROCÉDÉS ET COMPOSITIONS IN VITRO PERMETTANT D'AMÉLIORER L'ACTIVATION DE CELLULES DENDRITIQUES ET DE CELLULES T, ET PERMETTANT D'INDUIRE UNE RÉPONSE IMMUNITAIRE TH -1

(57) Abstract:[color=red]
(EN): The present disclosure provides compositions and in vitro or ex vivo methods for obtaining an enhanced antigen specific Th1 immune response. The compositions can comprise activation enhanced dendritic cells or T cells produced in vitro. The methods comprise contacting immature dendritic cells with a maturation agent that comprises a dendritic cell maturation agent, interferon y and an inflammation-activating lipid which can produced Received at International Bureau: 23 October 2020 (23.10.2020)

Information valid as of: 19 March 2021 (19.03.2021)

Report generated on: 25 December 2021 (25.12.2021)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2021/071977 15 April 2021 (15.04.2021) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2020/054621 07 October 2020 (07.10.2020) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/912,005 (US) 07 October 2019 (07.10.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 39/00 (2006.01)

(71) Applicant(s):
NORTHWEST BIOTHERAPEUTICS, INC. [US/US]; 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)
BOSCH, Marnix, Leo [--/--]; Statenplein 6 2582EX 's Gravenhage (NL) (for all designated states)
POWERS, Linda, F. [--/--]; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)
BOYNTON, Alton, L. [US/US]; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)

(72) Inventor(s):
BOSCH, Marnix, Leo; Statenplein 6 2582EX 's Gravenhage (NL)
POWERS, Linda, F.; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US)
BOYNTON, Alton, L.; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US)

(74) Agent(s):
POOR, Brian, W.; Christensen O'Connor Johnson Kindness PLLC 1201 Third Avenue, Suite 3600 Seattle, WA 98101 (US)

(54) Title (EN): IN VITRO METHODS AND COMPOSITIONS FOR ENHANCING THE ACTIVATION OF DENDRITIC CELLS AND T CELLS, AND FOR INDUCING A TH-1 IMMUNE RESPONSE
(54) Title (FR): PROCÉDÉS ET COMPOSITIONS IN VITRO PERMETTANT D'AMÉLIORER L'ACTIVATION DE CELLULES DENDRITIQUES ET DE CELLULES T, ET PERMETTANT D'INDUIRE UNE RÉPONSE IMMUNITAIRE TH -1

(57) Abstract:
(EN): The present disclosure provides compositions and in vitro or ex vivo methods for obtaining an enhanced antigen specific Th1 immune response. The compositions can comprise activation enhanced dendritic cells or T cells produced in vitro. The methods comprise contacting immature dendritic cells with a maturation agent that comprises a dendritic cell maturation agent, interferon ? and an inflammation-activating lipid which can produce hyperactivated dendritic cells. The method can further comprise contacting the maturing dendritic cells with a predetermined antigen during maturation. An in vitro or ex vivo method is also provided wherein the hyperactive dendritic cells can be used to induce naive T cell activation, where the activated T cells can be formulated for administration to an individual in need of such treatment.
(FR): La présente divulgation concerne des compositions et des procédés in vitro ou ex vivo permettant d'obtenir une réponse immunitaire Th1 spécifique à un antigène améliorée. Les compositions peuvent comprendre des cellules dendritiques ou des cellules T améliorées par activation produites in vitro. Les procédés consistent à mettre en contact des cellules dendritiques immatures avec un agent de maturation qui comprend un agent de maturation de cellules dendritiques, l'interféron ? et un lipide d'activation d'inflammation qui peut produire des cellules dendritiques hyperactivées. Le procédé peut en outre consister à mettre en contact des cellules dendritiques de maturation avec un antigène prédéterminé pendant la maturation. L'invention concerne également un procédé in vitro ou ex vivo selon lequel les cellules dendritiques hyperactives peuvent être utilisées pour induire l'activation des cellules T naïves, les cellules T activées pouvant être formulées pour être administrées à un individu ayant besoin d'un tel traitement.

International search report:
Received at International Bureau: 18 March 2021 (18.03.2021) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate
Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii)) hyperactivated dendritic cells. The method can further comprise contacting the maturing dendritic cells with a predetermined antigen during maturation. An in vitro or ex vivo method is also provided wherein the hyperactive dendritic cells can be used to induce naive T cell activation, where the activated T cells can be formulated for administration to an individual in need of such treatment. [/color]
(FR): La présente divulgation concerne des compositions et des procédés in vitro ou ex vivo permettant d'obtenir une réponse immunitaire Th1 spécifique à un antigène améliorée. Les compositions peuvent comprendre des cellules dendritiques ou des cellules T améliorées par activation produites in vitro. Les procédés consistent à mettre en contact des cellules dendritiques immatures avec un agent de maturation qui comprend un agent de maturation de cellules dendritiques, l'interféron ? et un lipide d'activation d'inflammation qui peut produire des cellules dendritiques hyperactivées. Le procédé peut en outre consister à mettre en contact des cellules dendritiques de maturation avec un antigène prédéterminé pendant la maturation. L'invention concerne également un procédé in vitro ou ex vivo selon lequel les cellules dendritiques hyperactives peuvent être utilisées pour induire l'activation des cellules T naïves, les cellules T activées pouvant être formulées pour être administrées à un individu ayant besoin d'un tel traitement.

International search report:
Received at International Bureau: 18 March 2021 (18.03.2021) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate
Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))